SC II Acquisition, a blank check company targeting well-established businesses in growing industries, filed on Thursday with the SEC to raise up to $150 million in an initial public offering.
The company plans to raise $150 million by offering 15 million units at a price of $10.00. Each unit consists of one share of common stock and one right to receive one-fifth of one share upon the completion of an initial business combination.
SC II Acquisition is led by CEO and Director Menachem Shalom, the CEO of Nukkleus (Nasdaq: NUKK; -84%), and CFO Asaf Yarkoni, the CFO of both Kamari Pharma and Aroma Republic. The SPAC plans to target businesses that are established, with strong free cash flow potential, a competitive advantage, and experienced management teams withing growing sectors or cyclical opportunities.
Management's previous SPAC Kochav Defense Acquisition (KCHVU; +4% from $10 offer price) raised $220 million in May 2025, and is currently searching for a target.
The New York, NY-based company was founded in 2025 and plans to list on the Nasdaq under the symbol SCIIU. SC II Acquisition filed confidentially on August 8, 2025. D. Boral Capital is the sole bookrunner on the deal.
